Enzo Biochem Faces Delisting Concerns
| Field | Detail |
|---|---|
| Company | Enzo Biochem Inc |
| Form Type | 8-K |
| Filed Date | Apr 21, 2025 |
| Risk Level | high |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, regulatory
TL;DR
Enzo Biochem might get kicked off the exchange - big trouble ahead.
AI Summary
Enzo Biochem, Inc. filed an 8-K on April 21, 2025, to report a notice of delisting or failure to satisfy a continued listing rule or standard. The company is based in Farmingdale, New York, and its principal executive offices are located at 21 Executive Blvd.
Why It Matters
This filing indicates potential issues with Enzo Biochem's continued listing on a stock exchange, which could significantly impact its stock value and trading liquidity.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's operations and investor confidence.
Key Players & Entities
- Enzo Biochem, Inc. (company) — Registrant
- April 21, 2025 (date) — Date of earliest event reported
- Farmingdale, New York (location) — Principal executive offices location
- 21 Executive Blvd. (address) — Principal executive offices address
FAQ
What is the specific reason for Enzo Biochem's potential delisting?
The filing states it is a 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard,' but the specific rule or standard is not detailed in this excerpt.
When was this notice filed?
The report was filed as of April 21, 2025.
What is Enzo Biochem's primary business?
Enzo Biochem, Inc. is in the business of Biological Products (No Diagnostic Substances), with SIC code 2836.
Where are Enzo Biochem's principal executive offices located?
The principal executive offices are located at 21 Executive Blvd., Farmingdale, New York 11735.
What is the company's fiscal year end?
The company's fiscal year ends on July 31.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 21, 2025 regarding ENZO BIOCHEM INC.